Three-Pronged attack tested to tame deadly thyroid cancer before surgery
NCT ID NCT04675710
Summary
This study is testing a combination of three drugs given before surgery for patients with a very aggressive type of thyroid cancer that has a specific genetic change (BRAF V600E mutation). The goal is to shrink the tumor and make it easier to remove completely during surgery, which could help patients live longer. The trial will enroll about 30 patients to see if this approach is more effective than past treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYROID GLAND ANAPLASTIC CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cleveland Clinic Taussig Cancer Institute
Cleveland, Ohio, 44195, United States
-
Huntsman Cancer Institute at the University of Utah
Salt Lake City, Utah, 84112, United States
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
-
Mayo Clinic
Rochester, Minnesota, 55901, United States
-
Stanford School of Medicine
Stanford, California, 94304, United States
-
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan, 48109, United States
Conditions
Explore the condition pages connected to this study.